Undiscovered Gems In Asia Promising Stocks For August 2026

In recent weeks, Asian markets have shown resilience amid global economic shifts, with key indices reflecting a positive sentiment driven by technological advancements and easing geopolitical tensions. As investors navigate these dynamic conditions, identifying promising small-cap stocks in Asia can offer unique opportunities for growth, particularly those that are well-positioned to leverage regional economic trends and sector-specific strengths.

Top 10 Undiscovered Gems With Strong Fundamentals In Asia

Name	Debt To Equity	Revenue Growth	Earnings Growth	Health Rating
CNMC Goldmine Holdings	0.84%	32.52%	78.36%	★★★★★★
DeHua TB New Decoration MaterialLtd	0.63%	1.50%	2.14%	★★★★★★
Nippon Carbide Industries	14.39%	2.05%	-0.55%	★★★★★★
Ad-Sol Nissin	NA	7.22%	15.60%	★★★★★★
Base	NA	11.66%	17.63%	★★★★★★
Management SolutionsLtd	10.02%	26.20%	33.40%	★★★★★★
Zhejiang Jolly PharmaceuticalLTD	21.31%	17.83%	29.70%	★★★★★☆
Henan Lingrui Pharmaceutical	7.45%	9.15%	18.27%	★★★★★☆
uSonar	5.92%	15.93%	37.38%	★★★★★☆
Shengda ResourcesLtd	57.58%	8.61%	9.90%	★★★☆☆☆

Click here to see the full list of 121 stocks from our Asian Undiscovered Gems With Strong Fundamentals screener.

Here we highlight a subset of our preferred stocks from the screener.

Zhejiang Jolly PharmaceuticalLTD (SZSE:300181)

Simply Wall St Value Rating: ★★★★★☆

Overview: Zhejiang Jolly Pharmaceutical Co., LTD focuses on the research, production, and marketing of Chinese medicinal products both domestically and internationally, with a market capitalization of CN¥10.13 billion.

Operations: Zhejiang Jolly Pharmaceutical generates revenue primarily from the sale of Chinese medicinal products, both within China and internationally. The company has a market capitalization of CN¥10.13 billion, reflecting its position in the pharmaceutical industry.

Zhejiang Jolly Pharmaceutical, a nimble player in the pharmaceutical sector, offers an intriguing profile with its earnings growth of 19% over the past year, outpacing the industry average of -3.2%. This company seems to be trading at a bargain, valued at 58.1% below its estimated fair value. Its debt management appears prudent with a net debt to equity ratio of 0.7%, considered satisfactory within industry standards. Furthermore, interest payments on its debt are well covered by EBIT at 65.7 times coverage, reflecting strong financial health and potential for sustained future performance in this competitive market space.

• Get an in-depth perspective on Zhejiang Jolly PharmaceuticalLTD's performance by reading our health report here.

• Explore historical data to track Zhejiang Jolly PharmaceuticalLTD's performance over time in our Past section.

Yahagi ConstructionLtd (TSE:1870)

Simply Wall St Value Rating: ★★★★★★

Overview: Yahagi Construction Co., Ltd. operates in the construction, civil engineering, and real estate sectors in Japan with a market capitalization of approximately ¥88.18 billion.

Operations: The company's primary revenue streams are derived from its construction and civil engineering projects, along with real estate activities. It focuses on managing costs efficiently to optimize its net profit margin.

Yahagi Construction, a relatively small player in the industry, seems to be trading at 35.8% below its estimated fair value, offering potential for investors seeking undervalued opportunities. Despite reporting a drop in sales from ¥5.45 billion to ¥1.05 billion and revenue from ¥41.15 billion to ¥31.60 billion year-over-year for Q1 2026, net income rose to ¥2.95 billion from ¥2.56 billion, indicating improved profitability with earnings per share climbing from ¥59.52 to ¥68.4 yen per share over the same period. With its debt-to-equity ratio reduced significantly over five years and interest well covered by EBIT at 103 times coverage, Yahagi shows financial resilience despite slower growth compared to industry peers last year (16% vs 28%).

• Navigate through the intricacies of Yahagi ConstructionLtd with our comprehensive health report here.

• Evaluate Yahagi ConstructionLtd's historical performance by accessing our past performance report.

Kitazato (TSE:368A)

Simply Wall St Value Rating: ★★★★★★

Overview: Kitazato Corporation engages in the research, development, manufacturing, and marketing of medical devices and related products for fertility treatment, with a market capitalization of ¥61.64 billion.

Operations: The company's primary revenue stream is from its Medical Equipment Business, generating ¥11.53 billion.

Kitazato, a nimble player in the medical equipment sector, showcases impressive financial health with no debt for five years and high-quality earnings. Trading at 36.5% below estimated fair value, it offers good relative value compared to peers. Recent strategic moves include a joint venture in India with Repro Lifesciences LLP to bolster market presence and regulatory compliance. The company anticipates net sales of ¥11.35 billion and operating profit of ¥6.12 billion for fiscal year 2027, alongside maintaining dividends at ¥41 per share from last year, signaling steady shareholder returns amidst expansion efforts.

• Click here to discover the nuances of Kitazato with our detailed analytical health report.

• Assess Kitazato's past performance with our detailed historical performance reports.

Turning Ideas Into Actions

• Reveal the 121 hidden gems among our Asian Undiscovered Gems With Strong Fundamentals screener with a single click here.
• Shareholder in one or more of these companies? Ensure you're never caught off-guard by adding your portfolio in Simply Wall St for timely alerts on significant stock developments.
• Invest smarter with the free Simply Wall St app providing detailed insights into every stock market around the globe.

Interested In Other Possibilities?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com